Literature DB >> 6270665

Rapid purification of a high-affinity plasminogen activator from human blood plasma by specific adsorption on fibrin/Celite.

S S Husain, B Lipinski, V Greuwich.   

Abstract

A preparation of fibrin precipitated over a solid Celite (diatomaceous earth) matrix that selectively binds 50-70% of the plasminogen activator present in human blood plasma is described. Affinity chromatography of plasma on fibrin/Celite followed by gel filtration led to a 29,000-fold purification of the plasminogen activator. The activator, referred to as the high-affinity plasminogen activator, is characterized by its ability to be strongly adsorbed by fibrin. Smaller amounts of other plasminogen activators and essentially all plasminogen were not bound to fibrin. The high-affinity plasminogen activator is a single-chain unstable protease with a molecular weight of 65,000-70,000. The high-affinity plasminogen activator has a low specific activity (500 CTA units/mg) compared to tissue or urine plasminogen activators (100,000-200,000 CTA units/mg) (CTA, Committee on Thrombolytic Agents).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6270665      PMCID: PMC319770          DOI: 10.1073/pnas.78.7.4265

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  19 in total

1.  Isolation of plasminogen activator from human plasma by chromatography on lysine-sepharose.

Authors:  R Radcliffe; T Heinze
Journal:  Arch Biochem Biophys       Date:  1978-07       Impact factor: 4.013

2.  Purification and characterization of human vascular plasminogen activator derived from blood vessel perfusates.

Authors:  B R Binder; J Spragg; K F Austen
Journal:  J Biol Chem       Date:  1979-03-25       Impact factor: 5.157

3.  On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin.

Authors:  I Rákóczi; B Wiman; D Collen
Journal:  Biochim Biophys Acta       Date:  1978-05-03

4.  Purification and properties of a plasminogen activator from pig heart.

Authors:  E R Cole; F W Bachmann
Journal:  J Biol Chem       Date:  1977-06-10       Impact factor: 5.157

Review 5.  The role of serine proteases in the blood coagulation cascade.

Authors:  E W Davie; K Fujikawa; K Kurachi; W Kisiel
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1979

Review 6.  Estimation of molecular size and molecular weights of biological compounds by gel filtration.

Authors:  P Andrews
Journal:  Methods Biochem Anal       Date:  1970

7.  Differences in the binding to fibrin of urokinase and tissue plasminogen activator.

Authors:  S Thorsen; P Glas-Greenwalt; T Astrup
Journal:  Thromb Diath Haemorrh       Date:  1972-08-31

8.  The isolation and characterization of plasminogen activators (urokinase) from human urine.

Authors:  W F White; G H Barlow; M M Mozen
Journal:  Biochemistry       Date:  1966-07       Impact factor: 3.162

9.  A simplification of the protein assay method of Lowry et al. which is more generally applicable.

Authors:  G L Peterson
Journal:  Anal Biochem       Date:  1977-12       Impact factor: 3.365

10.  The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator derived from cadaver limbs.

Authors:  V Gurewich; E Hyde; B Lipinski
Journal:  Blood       Date:  1975-10       Impact factor: 22.113

View more
  5 in total

1.  Effector-assisted refolding of recombinant tissue-plasminogen activator produced in Escherichia coli.

Authors:  H Grunfeld; A Patel; A Shatzman; A H Nishikawa
Journal:  Appl Biochem Biotechnol       Date:  1992-05       Impact factor: 2.926

2.  Monoclonal antibodies to human urokinase identify the single-chain pro-urokinase precursor.

Authors:  G Salerno; P Verde; M L Nolli; A Corti; H Szöts; T Meo; J Johnson; S Bullock; G Cassani; F Blasi
Journal:  Proc Natl Acad Sci U S A       Date:  1984-01       Impact factor: 11.205

3.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species.

Authors:  V Gurewich; R Pannell; S Louie; P Kelley; R L Suddith; R Greenlee
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

Review 4.  Modification of fibrin structure as a possible cause of thrombolytic resistance.

Authors:  Boguslaw Lipinski
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

Review 5.  Why so little progress in therapeutic thrombolysis? The current state of the art and prospects for improvement.

Authors:  Victor Gurewich
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.